Metis Global Partners LLC Grows Position in Illumina, Inc. (NASDAQ:ILMN)

Metis Global Partners LLC lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.1% in the 3rd quarter, Holdings Channel reports. The firm owned 3,575 shares of the life sciences company’s stock after acquiring an additional 299 shares during the period. Metis Global Partners LLC’s holdings in Illumina were worth $466,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc lifted its position in Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. purchased a new stake in shares of Illumina during the 2nd quarter valued at $34,000. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in Illumina in the second quarter worth $61,000. Finally, Mizuho Securities Co. Ltd. bought a new position in Illumina in the second quarter valued at $63,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

NASDAQ:ILMN opened at $130.74 on Tuesday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm’s fifty day simple moving average is $139.82 and its 200 day simple moving average is $124.35. The stock has a market cap of $20.74 billion, a P/E ratio of -13.13 and a beta of 1.13. Illumina, Inc. has a twelve month low of $93.39 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the previous year, the firm posted $0.33 EPS. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. As a group, research analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on ILMN shares. StockNews.com began coverage on Illumina in a research note on Thursday, August 29th. They set a “buy” rating for the company. Scotiabank cut their target price on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research note on Thursday, August 15th. Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research report on Wednesday, August 28th. Piper Sandler lowered their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Finally, Daiwa America raised shares of Illumina to a “strong-buy” rating in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Illumina presently has an average rating of “Moderate Buy” and an average price target of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.